Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4133 Clinical impact and prognosis of patients with Si-NET and bone metastases – Do they matter?

Introduction: The prevalence of bone metastases (BM) in small intestinal neuroendocrine tumors (Si-NET) ranges from 5 to 23 %.

Conference:

Presenting Author: Wedin M

Authors: Wedin M, Daskalakis K, Tiensuu Janson E, Sundin A, Wallin G,

Keywords: bone metastases, si-net, Neuroendocrine Neoplasm,

#4031 68-Gallium DOTANOC PET/CT pitfall in adnexal tumor

Introduction: PET/CT with 68Ga-DOTA is a commonly used tool in the baseline evaluation and follow-up of NETs due to its high specificity and sensitivity, showing better performance than CT in detecting primary and metastatic disease. However, we must know more about its normal physiological distribution, its variation in pathologies, and the possibility of confusion with benign processes to optimize its interpretation.

Conference:

Presenting Author:

Authors: González Devia D, Chaar-Lugo A, Rojas-Camacho J, Londoño-Schimmer E, Buriticá-Cifuentes C,

Keywords: Neuroendocrine tumor, 68Ga-DOTANOC, PET/CT, Rectal neuroendocrine tumor, Adnexal tumor, Pitfalls,

#3975 Patterns of radiotracer uptake in patients with resectable lung carcinoids undergoing preoperative functional imaging

Introduction: There is paucity of real-world data on the use of preoperative functional imaging (PFI) in patients (pts) with lung carcinoids (LC), and the association of radiotracer uptake (RU) with histology/outcomes.

Conference:

Presenting Author: Diamantopoulos L

Authors: Diamantopoulos L, Dimou A, Parikh K, Shanshal M, Schwecke A,

Keywords: carcinoid, lung, gallium, pet, somatostatin,